YD Bio Signs LOI to Buy Safe Save Medical, Bolstering Immunocell Therapy Portfolio

YD Bio (NASDAQ: YDBO) signed a non-binding letter of intent on January 29, 2026, to acquire Safe Save Medical, aiming to expand its immunocell therapy capabilities and market leadership. The acquisition targets Safe Save’s proprietary T-cell expansion and tumor-targeting platforms, which complement YD Bio’s existing pipeline in solid tumor treatments. Financial terms were not disclosed, pending due diligence and definitive agreement. YD Bio stated the deal would accelerate clinical development timelines and broaden its addressable patient population. Safe Save Medical, privately held, has completed Phase I trials for two autologous cell therapies. YD Bio expects the transaction to close by Q3 2026, subject to regulatory approvals. Shares of YDBO rose 4.7% in after-hours trading following the announcement.